Camena Bioscience

United Kingdom - Cambridge

• 04/07/2023
• Series A
• $9,901,000

Our mission is to enable synthetic biologists, by using our technology to unlock access to genes with unparalleled accuracy.

We produce genes for a range of biotechnology customers including those in the pharmaceutical, agriculture and diagnostics sectors. Our technology offers access to long and complex gene sequences, which are normally difficult to produce. We are based in Cambridge UK, but we serve companies across the world.

Camena's technology is positioned to enable researchers and the synthetic biology revolution.

Related People

Steve HarveyFounder

United Kingdom - Saffron Walden, England

You're ordering a gene, but the sequence is rejected because it's too 'complex'.

BUT if you change that bit of sequence and the coding sequence for another bit, everything will be ok?!

Then, after two months, you get a note saying it failed QC. And you are still standing at the starting line.

Sound familiar?

-----

For 7 years, we have focused on improving DNA and gene synthesis.

From day 1 our mission has been to develop THE leading DNA synthesis technology.

Simply, we want our technology to enable you. We don't want you to be held back by limiting tools.

-----

I post messages on LinkedIn about our company's mission and latest news. I also try to help others that are building something new.

👉 Follow me to keep up with our latest developments.
👉 Or message me to say hi.

LinkedIn https://www.linkedin.com/in/steve-harvey-camenabio/